APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

SAI Life Sciences / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sai-life-sciences" target="_blank" data-smartkarma-citation="entities:43724:1" rel="noopener">SAI Life Sciences (SAILS12 IN)</a> is looking to raise up to US$360m in its upcoming India IPO.</li>
<li>Sai Life Sciences is a contract research, development and manufacturing organisation providing end-to-end services across drug discovery, development and manufacturing value-chain, for small to global pharmaceutical innovators and biotechnology firms.</li>
<li>In this note, we talk about the company’s historical performance.</li>
</ul>



SAI Life Sciences (SAILS12 IN) is looking to raise up to US$360m in its upcoming India IPO.
Sai Life Sciences is a contract research, development and manufacturing organisation providing end-to-end services across drug discovery, development and manufacturing value-chain, for small to global pharmaceutical innovators and biotechnology firms.
In this note, we talk about the company’s historical performance.


Sai Life Sciences Pre-IPO - Portfolio Expansion and Increased Production Capacity to Drive Growth

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Elevance Health's third-quarter earnings reveal a mixed performance influenced by elevated medical costs, particularly in the Medicaid sector.</li><li>The adjusted diluted earnings per share came in at $8.37, slightly below the company's expectations, attributed primarily to elevated medical costs in the Medicaid business.</li><li>Consequently, Elevance Health has revised its full-year guidance downward to an adjusted EPS of approximately $33.</li></ul>

Elevance Health's third-quarter earnings reveal a mixed performance influenced by elevated medical costs, particularly in the Medicaid sector.The adjusted diluted earnings per share came in at $8.37, slightly below the company's expectations, attributed primarily to elevated medical costs in the Medicaid business.Consequently, Elevance Health has revised its full-year guidance downward to an adjusted EPS of approximately $33.

Elevance Health: Can Its Carelon Services Expansion & Integration Give Them A Competitive Advantage? - Major Drivers

<ul><li>Elevance Health recently reported its first-quarter results for the 2024 fiscal year, showcasing a blend of strategic accomplishments and agile responses to ongoing industry shifts.</li><li>The company announced earnings per share (EPS) on a GAAP basis of $9.59 and an adjusted diluted EPS of $10.64, indicating a robust growth of 12.5%.</li><li>This performance was underpinned by disciplined execution across Elevance Health's strategic initiatives in a dynamically evolving healthcare landscape.</li></ul>

Elevance Health recently reported its first-quarter results for the 2024 fiscal year, showcasing a blend of strategic accomplishments and agile responses to ongoing industry shifts.The company announced earnings per share (EPS) on a GAAP basis of $9.59 and an adjusted diluted EPS of $10.64, indicating a robust growth of 12.5%.This performance was underpinned by disciplined execution across Elevance Health's strategic initiatives in a dynamically evolving healthcare landscape.

Elevance Health Inc.:  How Is The Expansion of Value-Based Care Initiatives Panning Out? - Major Drivers

<ul><li>Elevance Health delivered mixed results for the previous quarter, with revenues well below analyst expectations, but managed an earnings beat.</li><li>However, the adjusted earnings per share demonstrated remarkable growth, reaching $8.99, marking a significant 20% increase compared to the same quarter in 2022.</li><li>Elevance Health has seen positive results in its Health Benefits division, specifically in the commercial risk business.</li></ul>

Elevance Health delivered mixed results for the previous quarter, with revenues well below analyst expectations, but managed an earnings beat.However, the adjusted earnings per share demonstrated remarkable growth, reaching $8.99, marking a significant 20% increase compared to the same quarter in 2022.Elevance Health has seen positive results in its Health Benefits division, specifically in the commercial risk business.

Elevance Health Inc.: The Future of Comprehensive Healthcare! - Major Drivers

<ul><li>Elevance Health managed to exceed analyst expectations in terms of revenue as well as earnings.</li><li>This strong result was driven by solid execution and progress in its mission to become a trusted health partner for life.</li><li>They achieved double-digit growth in GAAP and adjusted earnings per share, raising their adjusted earnings outlook for the year.</li></ul>

Elevance Health managed to exceed analyst expectations in terms of revenue as well as earnings.This strong result was driven by solid execution and progress in its mission to become a trusted health partner for life.They achieved double-digit growth in GAAP and adjusted earnings per share, raising their adjusted earnings outlook for the year.

Elevance Health Inc.: An Unstoppable Force Revolutionizing Healthcare? – Key Drivers

United States

Elevance Health, Inc. operates as a health benefits company. The Company provides health, dental and vision, and pharmacy benefits, as well as life insurance, and life and disability insurance benefits. Elevance Health offers a broad spectrum of network-based managed care plans to large and small employer, individual, medicaid, and medicare markets.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Elevance Health (ELV US)

Sai Life Sciences Pre-IPO - Portfolio Expansion and Increased Production Capacity to Drive Growth

Sai Life Sciences is looking to raise up to US$360m in its upcoming India IPO. In this note, we talk about the company’s historical performance.

Akshat Shah

Elevance Health: Can Its Carelon Services Expansion & Integration Give Them A Competitive Advantage? - Major Drivers

Elevance Health's third-quarter earnings reveal a mixed performance influenced by elevated medical costs, particularly in the Medicaid sector. The...

Baptista Research

Elevance Health Inc.: How Is The Expansion of Value-Based Care Initiatives Panning Out? - Major Drivers

Elevance Health recently reported its first-quarter results for the 2024 fiscal year, showcasing a blend of strategic accomplishments and agile...

Baptista Research

Elevance Health Inc.: The Future of Comprehensive Healthcare! - Major Drivers

Elevance Health delivered mixed results for the previous quarter, with revenues well below analyst expectations, but managed an earnings...

Baptista Research

Elevance Health Inc.: An Unstoppable Force Revolutionizing Healthcare? – Key Drivers

Elevance Health managed to exceed analyst expectations in terms of revenue as well as earnings. This strong result was driven by solid execution...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)